.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Julphar
Dow
Deloitte
Cipla
Accenture
Johnson and Johnson
Moodys
Merck
Baxter

Generated: December 16, 2017

DrugPatentWatch Database Preview

TRIAMCINOLONE ACETONIDE - Generic Drug Details

« Back to Dashboard

What are the generic sources for triamcinolone acetonide and what is the scope of triamcinolone acetonide freedom to operate?

Triamcinolone acetonide
is the generic ingredient in twenty-five branded drugs marketed by Abbvie, Sanofi Aventis Us, Astellas, Ivax Pharms, Delcor Asset Corp, Teva, Solvay, Actavis Mid Atlantic, Alpharma Us Pharms, Ambix, Fougera Pharms, G And W Labs, Glenmark Pharms Ltd, Lupin Atlantis, Morton Grove, Mylan Pharms Inc, Perrigo New York, Pharmaderm, Pharmafair, Taro, Teligent Pharma Inc, Topiderm, Vintage, Crown Labs, Savage Labs, Flexion Theraps Inc, Apothecon, Parnell, Sandoz Inc, Watson Labs, Allergan, Novartis Pharms Corp, Akorn, G And W Labs Inc, Wockhardt, Wockhardt Eu Operatn, Glenmark Pharms, Cmp Pharma Inc, Lyne, Perrigo Israel, Ranbaxy Labs Ltd, Perrigo Uk Finco, and Riconpharma Llc, and is included in one hundred and twenty-two NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Triamcinolone acetonide has ninety-five patent family members in thirty-six countries.

There are fifty-one drug master file entries for triamcinolone acetonide. Eighty-five suppliers are listed for this compound.

Pharmacology for TRIAMCINOLONE ACETONIDE

Medical Subject Heading (MeSH) Categories for TRIAMCINOLONE ACETONIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
TaroTRIAMCINOLONE ACETONIDEtriamcinolone acetonideOINTMENT;TOPICAL040374-001Jun 5, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
AstellasARISTOCORT Atriamcinolone acetonideCREAM;TOPICAL083016-005Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
AstellasARISTOCORT Atriamcinolone acetonideOINTMENT;TOPICAL080745-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
AstellasARISTOCORT Atriamcinolone acetonideCREAM;TOPICAL088819-001Oct 16, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
AstellasARISTOCORT Atriamcinolone acetonideCREAM;TOPICAL088818-001Oct 16, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
TopidermTRIAMCINOLONE ACETONIDEtriamcinolone acetonideCREAM;TOPICAL089274-001Feb 21, 1989DISCNNoNo► Subscribe► Subscribe► Subscribe
AstellasARISTOCORT Atriamcinolone acetonideCREAM;TOPICAL083017-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Perrigo New YorkTRIAMCINOLONE ACETONIDEtriamcinolone acetonideCREAM;TOPICAL086415-001Approved Prior to Jan 1, 1982ATRXNoNo► Subscribe► Subscribe► Subscribe
AstellasARISTOCORT Atriamcinolone acetonideCREAM;TOPICAL083015-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
AstellasARISTOCORTtriamcinolone acetonideCREAM;TOPICAL083015-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: triamcinolone acetonide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis UsNASACORT ALLERGY 24 HOURtriamcinolone acetonideSPRAY, METERED;NASAL020468-002Oct 11, 2013► Subscribe► Subscribe
AbbvieAZMACORTtriamcinolone acetonideAEROSOL, METERED;INHALATION018117-001Apr 23, 1982► Subscribe► Subscribe
Sanofi Aventis UsNASACORT ALLERGY 24 HOURtriamcinolone acetonideSPRAY, METERED;NASAL020468-002Oct 11, 2013► Subscribe► Subscribe
Delcor Asset CorpKENALOG-Htriamcinolone acetonideCREAM;TOPICAL086240-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis UsNASACORT ALLERGY 24 HOURtriamcinolone acetonideSPRAY, METERED;NASAL020468-002Oct 11, 2013► Subscribe► Subscribe
Sanofi Aventis UsNASACORTtriamcinolone acetonideAEROSOL, METERED;NASAL019798-001Jul 11, 1991► Subscribe► Subscribe
AbbvieAZMACORTtriamcinolone acetonideAEROSOL, METERED;INHALATION018117-001Apr 23, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: triamcinolone acetonide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,555,047Corticosteroids for the treatment of joint pain► Subscribe
7,122,206Aqueous-based pharmaceutical composition► Subscribe
6,375,984 Aqueous-based pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: triamcinolone acetonide

Country Document Number Estimated Expiration
South Korea20130093101► Subscribe
Uruguay31699► Subscribe
Australia2011285691► Subscribe
Bulgaria64585► Subscribe
Brazil9710115► Subscribe
Bulgaria103127► Subscribe
Colombia6700827► Subscribe
Poland194269► Subscribe
World Intellectual Property Organization (WIPO)2012019009► Subscribe
Australia737506► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Covington
QuintilesIMS
Boehringer Ingelheim
Teva
Deloitte
Medtronic
Johnson and Johnson
US Department of Justice
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot